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Prior investigations show that signaling activation through pattern recognition receptors 
can directly impact a number of inflammatory lung diseases. While toll-like receptor (TLR) 
7 agonists have raised interest for their ability to inhibit allergen-induced pathological 
changes in experimental asthma conditions, the putative benefit of this treatment is limited 
by adverse effects. Our aim was to evaluate the therapeutic potential of two PEGylated 
purine-like compounds, TMX-302 and TMX-306, characterized by TLR7 partial agonistic 
activity; therefore, the compounds are expected to induce lower local and systemic 
adverse reactions. In vitro approaches and translation to murine models of obstructive 
and restrictive lung diseases were explored. In vitro studies with human PBMCs showed 
that both TMX-302 and TMX-306 marginally affects cytokine production as compared 
with equivalent concentrations of the TLR7 full agonist, TMX-202. The PEGylated com-
pounds did not induce monocyte-derived DC maturation or B cell proliferation, differently 
from what observed after stimulation with TMX-202. Impact of PEGylated ligands on 
lung function and inflammatory changes was studied in animal models of acute lung 
injury, asthma, and silicosis following Lipopolysaccharide (LPS), allergen (ovalbumin), 
and silica inhalation, respectively. Subcutaneous injection of TMX-302 prevented LPS- 
and allergen-induced airway hyper-reactivity (AHR), leukocyte infiltration, and production 
of pro-inflammatory cytokines in the lung. However, intranasal instillation of TMX-302 
led to neutrophil infiltration and failed to prevent allergen-induced AHR, despite inhib-
iting leukocyte counts in the BAL. Aerosolized TMX-306 given prophylactically, but not 
therapeutically, inhibited pivotal asthma features. Interventional treatment with intranasal 
instillation of TMX-306 significantly reduced the pulmonary fibrogranulomatous response 
and the number of silica particles in lung interstitial space in silicotic mice. These findings 
highlight the potential of TMX-306, emphasizing its value in drug development for lung 
diseases, and particularly silicosis.
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inTrODUcTiOn
Inhalation of environmental airborne substances in the form of 
aeroallergens and particulate matter can result in allergic res-
piratory dysfunctions and pneumoconiosis, such as asthma and 
silicosis, respectively (1–4). Moreover, air pollutants may impact 
on allergic airway-related morbidity and mortality (5, 6). While 
asthma is among those diseases with an obstructive pulmonary 
function pattern (7), silicosis is pathologically characterized as a 
fibrogranulomatous disease with a restrictive pulmonary func-
tion profile (8). Both asthma and silicosis are highly prevalent 
worldwide, cause elevated socioeconomic costs, and can be 
fatal (3). Steroidal anti-inflammatory agent combined to bron-
chodilators is the best way of controlling asthma currently, but 
glucocorticoid resistance and adverse effects limit the efficacy of 
this treatment (2). The situation is even more alarming in case of 
silicosis, since no proper therapy is available (9).
Pulmonary inflammation is central in these diseases. In asthma, 
inflammation is driven by the adaptive arm of host immunity 
and reflects an aberrant immune response specifically against 
otherwise harmless environmental factors in genetically predis-
posed individuals (2). Yet, the basis of the inflammatory response 
mounted following exposure to occupational air  pollutants, 
such as crystalline silica particles, remains poorly understood 
(9). What is well established for both diseases, however, is the 
crucial role displayed by the airway wall as an immune-privileged 
innate barrier in which interdigitated dendritic cells (DCs), with 
the help of macrophages and epithelial cells, sense and respond 
to antigens, pollutant particles, and infectious microorganisms 
that traffic into the lung (10, 11). Upon intrusion, pathogens are 
recognized by pattern recognition receptors, and among them 
scavenger receptors (12–14) and Toll-like receptors (TLRs) play 
a pivotal role (15–18).
Toll-like receptors are located on the plasma membrane (TLR1, 
2, 4, 5, 6, and 10) and endosomal/lisosomal vesicles (TLR3, 7, 8, 
9, 11, 12, and 13) of immune cells (17). In humans, TLR1–10 are 
expressed by DCs, monocytes, macrophages, T cells, and B cells, 
and play important roles in their task of sensing and responding 
to “danger signals” presented by pathogens (19). All TLRs signal 
through the myeloid differentiation factor 88 (MyD88) adapter, 
with the exception of TLR3 that depends on TIR domain-
containing adaptor inducing IFNβ (TRIF) (20–22). No detectable 
signaling occurs through TLRs in the absence of MyD88 and 
TRIF (20, 21). Within the airways, activation of TLR7 decreases 
adaptive response in a mechanism associated with upregulation 
of type 1 interferon (15, 16, 23). Moreover, TLR7 rapidly relaxes 
human airways (24).
Several synthetic small TLR7 agonists have been studied for 
their potential use to treat asthma (25, 26), but with limited 
benefits because of local and systemic inflammatory reactions 
(27–29). More recent investigations indicate that the conjuga-
tion of TLR7 ligands with a 6-unit oligo-ethylene glycol (PEG) 
moiety showed potential to inhibit the course of inflammatory 
diseases, such as diabetes, with retained TLR7 specificity and 
attenuated non-specific inflammation (30, 31). We hypoth-
esize that PEGylated TLR7 partial agonists have potential to 
control not only allergic inflammatory lung diseases but also 
pneumoconiosis, with minimized adverse side effects. Hence, 
this study was undertaken in order to assess the impact of treat-
ment with two PEGylated purine-like compounds, TMX-302 and 
TMX-306, upon pulmonary inflammation and function changes 
triggered by Lipopolysaccharide (LPS), allergen, or silica particles 
in mice. TMX-302 was previously planned by linking a specific 
TLR7 ligand, 9-benzyl-8-hydroxy-2-(2-methoxyethoxy) adenine 
(1V136), to a six-unit polyethylene glycol (PEG) (30), whereas, 
TMX-306 resulted from a molecular simplification of TMX-302.
MaTerials anD MeThODs
reagents
The PEGylated TLR7 ligands TMX-302 [3-(1-(1-(4-((6-amino-
8-hydroxy-2-(2-methoxyethoxy)-9H-purin-9-yl)methyl)
phenyl)-1-oxo-5,8,11,14,17,20-hexaoxa-2-azadocosan-
22-yl)-1H-1,2,3-triazol-4-yl) propanoic acid] (MW = 791) and 
TMX-306 [1-(4-((6-amino-2-(2-methoxyethoxy)-8-oxo-7H- 
purin-9(8H)-yl) methyl) phenyl)-1-oxo-5,8,11,14,17,20-hexaoxa-
2-azatricosan-23-oic acid] (MW = 695), as well as the reference 
compound TMX-202 [2-(4-((6-Amino-2-(2-methoxyethoxy)-
8-oxo-7H-purin-9(8H)-yl) methyl) benzamido) ethyl 2,3-Bis 
(dodecanoyloxy) propyl phosphate] (MW = 920) were provided 
by Telormedix (Bioggio, CH). LPS (strain Escherichia coli 
O127:B8), ovalbumin (OVA) (grade V), and crystalline silica 
particles were purchased from Sigma Chemical, St. Louis, MO, 
USA. All the others were obtained as further indicated.
animals
Male A/J and Swiss Webster mice (18–20 g) were obtained from 
the Oswaldo Cruz Foundation breeding colony and housed in 
standard laboratory cages at 22–25°C, on a 12 h light/dark cycle, 
and fed with food and water ad libitum. All the protocols involv-
ing animal care and use were approved by the Animal Ethics 
Committee of the Oswaldo Cruz Institute (License L-030/2015). 
C57BL/6 mice, purchased from Harlan (Italy), were maintained 
in the animal facility of the Institute for Research in Biomedicine, 
and all procedures were approved by the veterinarian authorities 
from the local committee (Comitato Etico Cantonale del Ticino, 
Switzerland) with the authorization number TI17/2010.
human cell isolation and stimulation
Human PBMCs were isolated from buffy-coats (Central 
Laboratory of the Swiss Red Cross, Basel, Switzerland) using 
Ficoll-hypaque density centrifugation. Monocytes were isolated 
from PBMCs using CD14-magnetic beads (Miltenyi Biotec) and 
monocyte-derived dendritic cells (mo-DCs) generated in vitro, 
as previously described (32). Briefly, CD14+ cells were cultured 
for 4 days in complete medium supplemented with GM-CSF and 
IL-4 to induce mo-DCs differentiation. At day 4, medium was 
completely washed out, and cells were treated for 24 h with 10 μM 
of the indicated PEGylated TLR7 agonists or with vehicle only. 
At day 5, mo-DCs supernatant was collected to quantify the pro-
duction of pro-inflammatory cytokines by stimulated cells, and 
mo-DCs were stained for maturation markers. Total PBMCs were 
cultured for 24 h in complete medium, supplemented with dif-
ferent concentrations of PEGylated TLR7 agonists (1 or 10 μM), 
FigUre 1 | Treatment protocols. Mice were treated 1 and 24 h before 
LPS (25 μg/25 μL), and analyses were made 24 h after provocation (a). Mice 
were sensitized at days 0 and 14 and subjected to two consecutive daily 
injections of OVA (25 μg/25 μL) at days 19 and 20 postsensitization. 
TMX-302 was given subcutaneously (500 nmoles/mouse) or intranasally 
(65 nmoles/mouse), 1 and 24 h before OVA. TMX-306 was aerosolized 
(2 and 6 mg/mL, 30 min) under the same conditions. Analyses occurred 24 h 
after the last challenge (B). Mice were sensitized at days 0 and 7 and 
subjected to a series of four provocations with OVA (50 μg/25 μL) at days 14, 
21, 28, and 35 postsensitization. TMX-306 (70 nmoles/mouse) was 
intranasally injected at days 27 and 34 (c). Mice were challenged with 
crystalline silica particles at day 0 and subjected to three treatments with 
TMX-306 (70 nmoles/mouse) at days 15, 20, and 25 (D). Analyses were 
performed at day 30 post-silica.
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and the supernatant was collected to quantify pro-inflammatory 
cytokine release.
cytokines Detection in cell supernatant
The concentration of IL-1β, IL-6, IL-8, IL-10, IL-12, and TNF 
in the supernatant of human PBMCs and human mo-DCs was 
determined using the BD™ cytometric bead array (CBA) (human 
inflammatory cytokine kit – 551811, BD Biosciences), according 
to manufacturer’s instructions.
Flow cytometric analysis
For surface staining of human specimens, cell suspensions were 
incubated with the appropriate combination of the following 
monoclonal antibodies: CD19-PC5 (J3-119, Beckman Coulter), 
CD80-Brilliant Violet 421™ (2D10, BioLegend®), CD83-APC 
(HB15e, BioLegend®), CD86-APC (IT2.2, BioLegend®), and 
HLA-DR-V500 (G46-6, BD Horizon™). For surface staining 
of mouse specimens, cell suspensions were incubated with 
Fc-blocking antibody (Bioxcell, 2.4G2) to avoid unspecific 
Fc-Receptor binding. After washing, the cells were incubated 
with the appropriate combination of the following  antibodies: 
CD11b-PECy7 (M1/70, BioLegend®), Ly6G-PE (1A8, BD 
Biosciences), Ly6C-Biotin (AL-21, BD Biosciences), CD3-
APC(17A2, BioLegend®), CD45R-B220-PerCP-Cy5.5 (RA3-6B2, 
eBiosciences). To detect anti-Ly6C-Biotin antibody binding, cells 
were subsequently stained with streptavidin-FITC (Dako). The 
samples were acquired with BD LSRFortessa (BD Biosciences), 
and results were analyzed with FlowJo software (Tree Star, Inc.).
B lymphocytes Proliferation
Total human PBMCs were stained with 5  μM carboxyfluores-
cein succinimidyl ester (CFSE), using CellTrace™ CFSE Cell 
Proliferation kit (Invitrogen Molecular Probes, C34554), according 
to manufacturer’s instructions, and cultured in complete medium 
supplemented with 10 μM of the indicated PEGylated TLR7 ago-
nists for 4 days. At day 4, B lymphocytes were stained with an anti-
CD19 antibody, and proliferation was assessed by CFSE dilution.
leukocyte Mobilization from Bone Marrow
Age- and sex-matched mice (6–8 weeks) were randomly assigned 
to two groups, which were injected intraperitoneally with sterile 
saline (n = 5) or 200 nmoles of TMX-306 (n = 5). After 24 h, mice 
were sacrificed, and cellular suspension was obtained by blood, 
spleen, and bone marrow and analyzed by flow cytometry.
lPs-induced inflammation
A/J mice were exposed to a single dose of LPS (25 μg/mouse) 
or phosphate buffered solution (PBS) by intranasal route. The 
analyses were performed 24 h after stimulation. Treatment with 
TMX-302 (500 nmoles/mouse) was performed subcutaneously, 
1 and 24 h prior to LPS exposure (Figure 1A).
Ovalbumin-induced inflammation
A/J mice were sensitized, subcutaneously, with 50  μg of OVA 
and 5  mg of aluminum hydroxide dissolved in 0.2  mL PBS. 
Two protocols to induce the allergic response were used. For 
the short-term protocol (Figure  1B), mice were sensitized at 
day 0, boosted on day 14, and then exposed to intranasal OVA 
(25 μg/mouse), or sterile PBS, at days 19 and 20 (33). Treated 
animals received TMX-302 either by subcutaneous (500 nmoles/
mouse) or intranasal route (65 nmoles/mouse), 1 and 24 h before 
allergen challenge. In another set of experiments, mice were 
exposed to aerosol of TMX-306 (2 and 6 mg/mL) also following 
protocol B (Figure 1B). For the interventional treatment, mice 
were sensitized at day 0, boosted at day 7, and then challenged 
with OVA (50 μg/mouse), or PBS, days 14, 21, 28, and 35 post-
sensitization (4). Treated animals received intranasal TMX-306 
(70  nmoles/mouse) or oral dexamethasone (1  mg/kg), at days 
26 and 33 postsensitization. In both protocols, the analyses were 
performed 24 h after the last OVA challenge (Figure 1C).
silica-induced chronic inflammation
Swiss Webster mice were exposed to crystalline silica particles 
(10  mg/mouse) (size 0.5–10 μm) or sterile PBS as control (1). 
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The interventional treatment with TMX-306 (70 nmoles/mouse) 
was given at days 15, 20, and 25, and the analyses performed at 
day 30 after silica instillation (Figure 1D).
invasive assessment of respiratory 
Mechanics
Mice were anesthetized with nembutal (60  mg/kg), and neu-
romuscular activity was blocked with bromide pancuronium 
(1  mg/kg). Lung resistance (cmH2O  s/mL) and elastance (mL/
cmH2O) were assessed in tracheostomized and mechanically 
ventilated mice using a FinePointe R/C Buxco Platform (Buxco® 
Electronics, Sharon, CT, USA) (1).
Bronchoalveolar lavage
Airways were lavaged by a polyethylene cannula, inserted into 
the trachea, with two consecutive instillations of 0.75 mL of PBS 
containing 10  mM of EDTA. Bronchoalveolar Lavage (BAL) 
was centrifuged at 300 × g for 10 min at 4°C, and the cell pellet 
was resuspended in 0.25 mL of PBS for leukocyte enumeration. 
Total cells were counted in Neubauer chamber by means of 
light microscopy, after dilution of samples in Turk solution. The 
differential analysis was performed in cytocentrifuged smears 
stained for identification of mononuclear cells, neutrophils, and 
eosinophils by May-Grunwald-Giemsa under an oil immersion 
objective and light microscope (BX51, Olympus) (34).
histology
The left lung was removed, fixed in Milloning buffer solution 
(pH 7.4) with 4% paraformaldehyde to preserve pulmonary 
architecture. Briefly, samples were embedded in paraffin (Sigma-
Aldrich), and 4  μm-thick sections were cut and stained with 
hematoxylin and eosin for quantification of granuloma area, 
Picrosirius for collagen fibers and Sirius Red (pH 10.2) for 
neutrophils and eosinophils counted in the parenchyma and 
in peribronchiolar area, respectively. Slides were scanned with 
3DHISTECH–Pannoramic MIDI whole slide scanner (capture 
with a 20× objective lens) and the resulting images analyzed with 
CaseViewer 3.3, Pannoramic Viewer 1.15.4, and HistoQuant 
softwares (3DHISTECH). Silica crystals were analyzed, in 15 
independent fields, with a light microscope (Olympus BX50) 
equipped with polarizing attachment for detecting birefringent 
particles and Image-Pro Plus Version 4.
immunohistochemistry
Left lung samples were examined for immunohistochemical 
localization of TGF-β using paraffin-embedded sections. Primary 
anti-TGF-β1/2/3 (sc-7892) was obtained from Santa Cruz 
Biotechnology (Dallas, TX, USA). Secondary antibody HAF008 
was conjugated with horseradish peroxidase (HRP) and obtained 
from R&D Systems (Minneapolis, MN, USA). In negative con-
trols, primary antibody was omitted, and tissues were incubated 
with antibody diluent only. To improve visualization of the pri-
mary label, slides were counterstained with Mayer’s Hematoxylin 
(Lillie’s modification) as previously described (1). The slides were 
scanned with 3DHISTECH–Pannoramic MIDI and quantified as 
previously reported (1).
cytokine Quantification
Murine TNF-α, MIP-1α/CXCL-3, MIP-2/CXCL-2, IL-6, 
and eotaxin-2 levels were measured in the right lung tissue 
samples, which were homogenized in PBS containing 0.05% 
Triton X-100 and a protease inhibitor cocktail (Hoffmann-La 
Roche, Basel, Switzerland). Samples were quantified using 
commercially available ELISA kits (DuoSet system, R&D 
Systems, Minneapolis, MN, USA), according to the manufac-
turer’s instructions. The results were expressed as picograms of 
cytokine per right lung.
Protein Quantification
Total protein levels were measured by Bradford technique. 
Right lung tissue samples were homogenized in PBS 1 mL with 
Triton X-100 (0.1%), containing protease inhibitor COMPLETE 
(Hoffmann-La Roche Ltd., Switzerland). The results were 
expressed as micrograms of protein per right lung.
statistical analysis
Statistical analyzes were performed using GraphPad Prism 
Software, version 5.0 (USA). For in vitro experiments on human 
PBMCs, the analyses were performed with repeated measures 
two-way ANOVA followed by Tukey’s multiple comparison. 
For in  vivo experiments, the analyses were done with one-way 
ANOVA followed by the Student–Newman–Keuls test or two-
way ANOVA with post  hoc Bonferroni correction. Statistical 
differences were considered significant if p values were less than 
0.05 (two-tailed tests).
resUlTs
Pegylated Tlr7 Partial agonists activity 
of human leukocytes
The effects of the two 1V136 PEGylated derivatives, TMX-302 and 
TMX-306, on human PBMCs and on the maturation of mo-DCs, 
were assessed in cells from healthy donors. In vitro, none of the 
PEGylated compounds resulted to be toxic on PBMCs; with no 
relevant apoptosis induced after over night exposure to TMX-302 
or TMX-306 (10 μM, data not shown). Both TMX-302 and TMX-
306 induced a minimal cytokine production as compared to the 
TLR7 full agonist TMX-202 at 1 μM. When the compounds were 
used at high concentration (10  μM), we observed production 
only of IL–6 and IL–8 that was comparable to the one observed 
using TMX-202 (Figure 2). None of the tested PEGylated TLR7 
partial agonists induced relevant cytokine production by  mo-DCs 
(Figure  3A) or mo-DCs maturation (Figure  3B). Moreover, 
cytofluorimetric analysis on human PBMCs labeled with CFSE 
and incubated with the different compounds showed that the 
PEGylated partial agonists do not induce B cell proliferation 
(Figure 3C).
effect of TMX-302 on lPs-induced 
inflammation and airway hyper-reactivity
Subcutaneous pre-treatment with TMX-302 (500  nmoles/
mouse given twice), 1 and 24  h before LPS (protocol A, 
FigUre 2 | Concentration of IL1-β  (a), IL-6  (B), IL-12  (c), IL-8  (D), TNF-α  (e) and IL-10  (F) in the supernatant of human PBMCs, after 24 h stimulation with 
TMX-202, TMX-302 or TMX-306 at 1 or 10 μM. Data are presented as mean ± SEM from n = 6.
FigUre 3 | effect of Pegylated Tlr7-agonists on maturation of mo-Dcs or proliferation of B cells. (a) Concentration of the indicated inflammatory 
cytokines in the supernatant of mo-DCs (n = 6), after 24 h stimulation with TMX-202, TMX-302, or TMX-306 at 10 μM. Data are presented as mean values. 
(B) Frequency of mo-DCs expressing the maturation markers CD80, CD83, CD86, and HLA-DR, after 24 h stimulation with TMX-202, TMX-302, or TMX-306 at 
10 μM. Data are presented as mean values of three independent experiments. Dotted lines in (a,B) represent the amount of cytokines or expression of maturation 
markers in the absence of TLR7 stimulation. (c) B cell proliferation measured by CFSE dilutions after 4 days in culture with TMX-202, TMX-302, or TMX-306 at 
10 μM. One representative plot out of three experiments performed with cells from different donors is shown.
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Figure 1), reduced the increased lung elastance response noted 
in mice challenged with LPS (Figure 4A). As expected, LPS also 
caused protein extravasation (Figure  4B) and augmentation 
in total leukocyte levels, as indicated by enumeration of these 
cells in BAL effluents (Figure  4C) and lung histological sec-
tions (Figures 4D,G), in comparison to the respective negative 
TaBle 1 | effect of TMX-302 on cytokine/chemokine generation in the 
lung tissue of lPs-stimulated mice.
cytokine  
(pg/lung tissue)
PBs lPs lPs + TMX-302
TNF-α 97.5 ± 8.7 290.2 ± 49.2+ 178.9 ± 29.1*
MIP-1α 314.5 ± 48.6 1276.1 ± 277.7+  816.9 ± 120.6*
IL-6 280.2 ± 57.7 1131.1 ± 285.0+  777.6 ± 122.2
TMX-302 (500 nmoles/mouse) was given 1 h before LPS (25 μg), and the analyses 
were performed 24 h after LPS. Values represent the mean ± SEM from at least six 
animals.
+p < 0.05 vs. PBS-challenged group.
*p < 0.05 vs. LPS-challenged group.
FigUre 4 | effect of subcutaneous treatment with TMX-302 on lPs-induced inflammation in the lung of mice. (a) Lung elastance; (B) protein exudation; 
(c) leukocytes in BAL; (D) total leukocytes; and (e) polymorphonuclear in the lung tissue. Histological sections of lungs from animals instilled with (F) PBS, (g) LPS 
(25 μg/mouse), and (h) LPS and treated with TMX-302 (500 nmoles/mouse). Slides were stained with H&E. Scale bar = 200 μm. All the analyses were made 24 h 
after LPS stimulation. Values represent mean ± SEM from at least six animals. +p < 0.05 as compared to PBS-challenged group; *p < 0.05 as compared to 
LPS-challenged group.
March 2016 | Volume 7 | Article 956
Ferreira et al. TLR7 Ligands for Lung Diseases
Frontiers in Immunology | www.frontiersin.org
controls (Figures 4C,F). Neutrophils were the predominant leu-
kocyte subtype found in the bronchoalveolar space (Figure 4C) 
and lung parenchyma (Figures 4E,G). All these changes were 
significantly inhibited by the subcutaneous pre-treatment 
with TMX-302 (Figures  4B–E,H). Quantification of pro-
inflammatory cytokines and chemokines in lung homogenates 
in response to LPS revealed increased levels of TNF-α, MIP-1α, 
and IL-6, all of which appeared inhibited by TMX-302 though, 
in case of IL-6, the 40% blockade was not statistically significant 
(Table 1).
effect of TMX-302 on allergen-induced 
inflammation and airway hyper-reactivity
Confirming previous reports (33), OVA intranasal challenge of 
sensitized mice exacerbated both airway resistance (Figure 5A) 
and lung elastance responses (Figure 5B) to inhaled methacho-
line (3–27 mg/mL). Increased levels of leukocytes, mainly eosino-
phils, were detected in the BAL fluid (Figure 5C) as compared to 
control mice challenged with PBS. The same figures show that the 
pre-treatment with TMX-302 (500  nmoles/mouse, subcutane-
ous) (protocol B, Figure  1) prevented allergen-induced airway 
hyper-reactivity (AHR) and eosinophilic leukocyte accumulation 
(Figures 5A–C).
When the systemic prophylactic was replaced by the local 
prophylactic treatment with TMX-302 (65  nmoles/mouse, 
intranasal instillation) (protocol B, Figure 1), no more protective 
effect was seen for allergen-induced increased airway resistance 
(Figure  6A) and lung elastance (Figure  6B) in response to 
methacholine. Moreover, TMX-302 itself caused AHR in naive 
mice (Figures 6A,B). A significant blockade of the OVA-induced 
eosinophilic, but not neutrophilic infiltration, was apparent 
following TMX-302, as observed in BAL samples (Figure  6C) 
and lung tissue samples (Figures  6D,E). Moreover, the nasal 
instillation of TMX-302 (65  nmoles/mouse) in naive mice led 
FigUre 5 | effect of subcutaneous treatment with TMX-302 on OVa-induced inflammation in the lung of mice. Lung function: (a) resistance and 
(B) elastance (c) total leukocytes in BAL. Animals were sensitized on days 0 and 7 and then challenged with OVA (25 μg/mouse) or PBS, on days 19 and 20. 
Treatment with TMX-302 (500 nmoles/mouse, subcutaneous) was given 1 h before each OVA challenge, and analyses were performed 24 h after 
the last stimulation. Values represent mean ± SEM from at least six animals. +p < 0.05 as compared to PBS-challenged group; *p < 0.05 as compared to 
OVA-challenged group.
FigUre 6 | effect of intranasal treatment with TMX-302 on OVa-induced inflammation in the lung of mice. Lung function: (a) resistance; (B) elastance, 
(c) total leukocytes in BAL, (D) tissue eosinophil numbers and (e) tissue neutrophil numbers. Animals were sensitized on days 0 and 7 and then challenged with 
OVA (25 μg/mouse) or PBS on days 19 and 20. Treatment with TMX-302 (65 nmoles/mouse, intranasal) was given 1 h before each OVA challenge, and analyses 
were performed 24 h after the last stimulation. Values represent mean ± SEM from at least six animals. +p < 0.05 as compared to PBS-challenged group; *p < 0.05 
as compared to OVA-challenged group.
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TaBle 2 | effect of TMX-302 on cytokine/chemokine generation in the 
lung tissue of allergen-stimulated mice.
cytokine (pg/
lung tissue)
PBs OVa OVa +  
TMX-302
TMX-302
MIP-1-α 117.2 ± 76.4 937.5 ± 169+ 1672.7 ± 295.1* 605.4 ± 84.9+
MIP-2 275.6 ± 70.6 665.6 ± 66.8+ 243.9 ± 68.7* 934.9 ± 126.8+
TNF-α 88.7 ± 7.6 138.9 ± 11.0+ 110.1 ± 8.7* 132.1 ± 11.2+
The analyses were performed 24 h after ovalbumin provocation, and values represent 
the mean ± SEM from at least six animals.
+p < 0.05 vs. PBS-challenge group.
*p < 0.05 vs. OVA-challenge group.
FigUre 7 | effect of aerosol treatment with TMX-306 on OVa-induced inflammation in the lung of mice. Lung function: (a) resistance, (B) elastance, and 
(c) peribronchiolar eosinophil infiltration. Animals were sensitized on days 0 and 7 and then challenged with OVA (25 μg/mouse) or PBS on days 19 and 20. 
Treatment with TMX-306 (2 and 6 mg/mL, aerosol) was given 1 h before each OVA challenge, and analyses were performed 24 h after the last stimulation. Values 
represent mean ± SEM from at least six animals. +p < 0.05 as compared to PBS-challenged group; *p < 0.05 as compared to OVA-challenged group.
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to neutrophil accumulations in the BAL fluid (Figure 6C) and, 
particularly, in the lung parenchyma (Figure 6E). As shown in 
Table 2, the intranasal instillation of TMX-302, despite inhibit-
ing OVA-induced TNF-α and MIP-2, clearly up-regulated 
OVA-induced MIP-1-α, and caused itself significant elevation of 
MIP-1α, MIP-2, and TNF-α levels in lung homogenates.
effect of TMX-306 on allergen-induced 
inflammation and airway hyper-reactivity
Once the topical administration, through intranasal instillation 
of TMX-302, was ineffective upon asthmatic changes and caused 
adverse events, the effects of the parent compound TMX-306 were 
investigated. As shown in Figure 7, the prophylactic treatment 
with aerosolized TMX-306 (6  mg/mL) (protocol B, Figure  1) 
prevented allergen-induced AHR, in respect to airway resistance 
(Figure  7A) and lung elastance (Figure  7B), as well as the 
 infiltration of eosinophils in the peribronchiolar zone (Figure 7C). 
When aerosolized at 2  mg/mL, TMX-306 prevented allergen-
induced AHR but not eosinophilic infiltration (Figures 7A–C).
We next assessed the effectiveness of TMX-306 (70 nmoles/
mouse, intranasal) on ongoing asthmatic changes according to 
the protocol C (Figure 1). Contrarily to dexamethasone, TMX-
306 failed to reduce AHR (Figures  8A,B) and peribronchiolar 
eosinophilic infiltration (Figure 8C) caused by OVA challenge, 
suggesting the lack of beneficial effects for the therapeutic treat-
ment with TMX-306 on allergen-induced pathological changes, 
under the conditions applied.
effect of TMX-306 on silica-induced 
inflammatory, Fibrotic, and 
respiratory changes
Initially, in order to assess if the PEGylated compound TMX-306 
would impact per se cell mobilization from the bone marrow as 
well as subsequent distribution in blood circulation and spleen, 
TMX-306 was injected intraperitoneally in mice. The results 
obtained indicate that this PEGylated analogue, at the dose of 
200  nmoles/mouse, does not affect cell mobilization and com-
partmentalization in wild type mice (Figure S1 in Supplementary 
Material).
The next step was the evaluation of the effect of TMX-306 
on experimental silicosis, which was performed in accordance 
to protocol D (Figure 1) and prior investigations (1, 35). Based 
FigUre 8 | effect of intranasal treatment with TMX-306 on OVa-induced inflammation in the lung of mice. Lung function: (a) resistance; (B) elastance, 
and (c) peribronchiolar eosinophil infiltration. Animals were sensitized on days 0 and 7 and then challenged with OVA (25 μg/mouse) or PBS on days 14, 21, 28, 
and 35. Animals were treated with TMX-306 (70 nmoles/mouse, intranasal) or dexamethasone (1 mg/Kg, oral) on days 26 and 22, 1 h before OVA challenge, and 
analyses performed 24 h after the last challenge. Values represent mean ± SEM from at least six animals. +p < 0.05 as compared to PBS-challenged group; 
*p < 0.05 as compared to OVA-challenged group.
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on the histologic analyzes of lung sections stained with H&E for 
assessment of granuloma (Figure 9, upper panels) and Picrosirius 
red for evaluation of fibrotic lesions (Figure 9, lower panels), it 
became clear that, compared to mice exposed to PBS (Figure 9A), 
those exposed to silica particles (Figure  9B) reacted with an 
intense granulomatous response, which occupied about 40% of 
the left pulmonary lobe 30  days postprovocation (Figure  9G). 
Moreover, a dense area of collagen fiber deposition appeared dis-
tributed in those spaces occupied by granuloma in silicotic mice 
(Figure  9E). Remarkably, both granuloma and fibrotic lesions 
caused by silica inhalation were clearly inhibited by the treatment 
with TMX-306 (70 nmoles/mouse), carried out at days 15, 20, and 
25 after silica provocation (Figures 9G,H, respectively).
Using immunohistochemistry technique based on anti-TGF-β 
staining, the quantitative assessment of expression of TGF-β 
under conditions of exposure to PBS, silica particles, or silica 
plus TMX-306 revealed significant increase in lung tissue levels 
of IL-TGF-β in samples recovered from mice exposed to silica 
particles (Figure  10B), as compared to those exposed to PBS 
(Figure  10A). Given through nasal instillation in the regime 
mentioned before, TMX-306 inhibited silica-induced produc-
tion of TGFβ (Figure 10C). The quantitative data are shown in 
Figure 10D.
effect of TMX-306 on silica Particle 
Diffusion in lung Parenchyma
In this study, we used a light microscope equipped with polarizing 
filters when examining lung tissue sections from mice exposed to 
silica particles. Having lung section from mice exposed to PBS 
as reference (Figure 11A), our findings confirmed the presence 
of numerous crystals of silica in sections from mice exposed 
to the particles, seen as small bluish bright specks, distributed 
throughout lung areas mainly those occupied by granuloma 
(Figure 11B). The amount of silica particles present in the inter-
stitial space appeared significantly reduced in mice treated with 
TMX-306 (70  nmoles/mouse) (Figure  11C). Quantitative data 
are shown in Figure 11D.
DiscUssiOn
Toll-like receptors play a crucial role in sensing and responding to 
respirable “dangerous triggers” including allergens and ambient 
pollutant particles, which may lead to asthma and pneumoco-
niosis (13, 36). Synthetic low molecular weight TLR7 agonists, 
including 1V136 and others, have been shown to down-regulate 
immune responses during inflammatory conditions (25, 26, 37, 
38). Additionally, PEGylation improves bioavailability and safety 
of these ligands (30, 39). The overall purpose of this study was to 
access the effects of 1V136 PEGylated derivatives on pulmonary 
inflammatory and functional changes caused by three distinct 
classes of pathogens, including LPS, allergen, and crystalline 
silica particles.
Our experiments revealed that both PEGylated derivatives 
TMX-302 and TMX-306 presented a marginal pro-inflammatory 
response, yielding a minimal production of inflammatory 
cytokines in human PBMCs, no mo-DC maturation or B cell 
FigUre 9 | effect of intranasal treatment with TMX-306 on granuloma formation (upper panels) and collagen deposition (lower panels) in  
silica-challenged mice. Histological sections of mouse lungs on day 30 after silica challenge (B,e) and treated with TMX-306 (70 nmoles/mouse, intranasal) (c,F). 
Animals instilled with PBS were used as controls (a,D). Animals were treated with TMX-306 (70 nmoles/mouse, intranasal) days 15, 20, and 25 post-silica. 
Morphometric analyzes are seen in (g) granuloma area and (h) collagen deposition. Slides were stained with H&E (upper panels) and Picrosirius red (lower panels). 
Scale bars, 200 μm. Values represent mean ± SEM from at least five animals. +P < 0.05 as compared to PBS-challenged group; *P < 0.05 as compared to 
silica-challenged group.
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proliferative responses, differently from the TLR7 full agonist 
used for comparison (TMX-202). In in  vivo settings, subcu-
taneous pre-treatment with TMX-302 prevented LPS- and 
allergen-induced lung inflammation and AHR, while its topical 
administration failed to prevent allergen-induced AHR, and 
caused itself neutrophil infiltration, in parallel with cytokine and 
chemokine generation. Administered topically, TMX-306 pre-
vented allergen-induced asthma changes, but did not modify 
them as given therapeutically. In contrast, in the silicosis 
model, interventional treatment with TMX-306 significantly 
reduced the pulmonary fibrogranulomatous response follow-
ing crystallized silica particle inhalation in mice. Altogether, 
these studies highlight the putative value of TMX-306 in drug 
development for silicosis.
As candidates to anti-inflammatory therapy, TLR7 ligands 
should ideally be able to push the innate system to a state of 
tolerance, with minimal pro-inflammatory effects. Actually, 
the safe therapeutic use of TLR7 agonists has been proved to 
be a difficult task because of the cytokine release syndrome 
and pharmacokinetic limitations (16). Prior investigations 
have demonstrated that the conjugation of these ligands to 
polysaccharides, serum albumin or PEG widely improved their 
pharmacokinetics and pharmacodynamics properties (30, 39, 
40). Accordingly, in our experiments assessing cytokine pro-
duction by human PBMCs in vitro, the PEGylated compounds 
TMX-302 and TMX-306, at 1  μM, were clearly less active 
than the reference compound TMX-202, producing marginal 
amounts of IL-1β, IL-6, IL-12p70, IL-8, or TNF. TMX-302 
and TMX-306 at 10 μM promoted only IL-6 and IL-8 release 
from human PBMCs, but failed to induce pro-inflammatory 
cytokine release by mo-DC and their maturation as well as B 
lymphocyte proliferation, which are hallmarks of TLR7 activa-
tion (41), supporting the interpretation that the two PEGylated 
1V136 derivatives are indeed suitable molecules for further 
in vivo investigations.
The immune-regulatory effects of TLR ligands, in more ample 
sense, are heterogeneous and complex. For instance, inhalation 
of the TLR4 agonist LPS exacerbates silica-induced fibrogranu-
lomatous pulmonary dysfunction in mice (42), but can attenuate 
ongoing asthmatic changes following long-term exposure of 
mice to allergen challenge (43). While investigating the thera-
peutic potential of TMX-302 and TMX-306, we have explored 
well-established murine models of acute lung injury (ALI) (44), 
asthma (4, 33, 34), and silicosis (1, 35). ALI is a severe clinical 
problem associated with elevated rates of morbidity and mortality 
worldwide (45). Triggered by LPS, a component of the cell wall of 
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FigUre 10 | effect of intranasal treatment with TMX-306 on TgF-β production in the lung tissue of silica-challenged mice. Samples were analyzed in 
animals instilled with PBS (a), silica (10 mg/mouse) (B), and silica treated with TMX-306 (70 nmoles/mouse, intranasal) (c) 30 days after silica challenge. Treatment 
with TMX-306 was performed at days 15, 20, and 25 post-silica. Quantitative analyses are seen in (D). Values represent mean ± SEM from at least six animals. 
+P < 0.05 as compared to PBS-challenged group; *P < 0.05 as compared to silica-challenged group.
FigUre 11 | TMX-306 reduces silica particles in lung tissue. Quantitative evaluation of silica particles was assessed in animals instilled with PBS (a), silica 
(10 mg/mouse) (B), and silica treated with TMX-306 (70 nmoles/mouse, intranasal) (c), 30 days after silica challenge. Quantitative analyses are seen in (D). 
Picrosirius red-stained sections were evaluated by light and polarized microscopy, respectively. Arrows indicate silica particles. Scale bar, 200 μm. Values represent 
mean ± SEM from at least seven animals. *P < 0.05 as compared to silica-challenged group.
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gram-negative bacteria, ALI is marked by pulmonary neutrophilic 
leukocyte infiltration, disruption of the endothelial and alveolar 
epithelial barrier, lung edema, and severe hypoxemia (45). We 
found that under conditions of intranasal instillation of LPS, the 
systemic pre-treatment with TMX-302 (500  nmoles/mouse), 
given subcutaneously 24 and 1  h before provocation, clearly 
inhibited the lung inflammatory changes, including the massive 
leukocyte accumulation in the bronchoalveolar space and lung 
parenchyma, plasma leakage and AHR-noted 24 h postchallenge. 
The protective effect of TMX-302 concerning leukocyte changes 
and respiratory function might be explained by the blockade of 
pro-inflammatory cytokine production, including TNF-α, IL-6 
and MIP-1α, as attested by measurements done in lung tissue 
samples. Recent studies emphasize the involvement of the adapter 
molecule MyD88 in the LPS-TLR4 signaling pathway followed 
by activation of NF-kappa B in ALI (46, 47), though this is still a 
debatable issue (48). However, since MyD88 is a pivotal adapter 
to all TLRs, except TLR3, the possibility does exist that TMX-302 
is acting here through induction of a tolerogenic mechanism 
accounted for by induction of cross-desensitization between 
TLR7 and TLR4 signaling pathways.
Differently from TLR4, TLR7 selectively detects viral RNA, 
leading to activation of T-helper cell (Th1) immune response 
and viral clearance. Several pieces of evidence suggest that TLR 
activation are protective against T-helper cell (Th2)-mediated 
diseases, such as asthma, possibly by interfering with the Th1 
versus Th2 immune balance (15, 16, 23). Additionally, activation 
of TLR7 expressed on CD4+ T cells and airway nerves can lead 
to anergy (49) and respiratory smooth muscle relaxation (24), 
respectively. TLR7 has also raised interest in asthma because 
respiratory viruses are a major cause of exacerbations. Notably, 
virus clearance depends on TLR-mediated Th1 response, which 
is down-regulated in the asthma Th2 microenvironment (50). We 
observed here that the systemic pre-treatment with TMX-302, 
given subcutaneously, prevented allergen-induced eosinophilic 
inflammatory infiltration and AHR in a short-term murine 
model of asthma. Nevertheless, the mucosal administration 
of TMX-302 (65  nmoles/mouse, intranasal instillation), 24 
and 1  h before provocation, failed to prevent allergen-induced 
AHR though inhibiting the accumulation of eosinophils in the 
bronchoalveolar space and tissue samples. Actually, TMX-302 
itself induced a significant increase in the levels of peribronchial 
neutrophils, in parallel with significant increase in the lung tissue 
production of MIP-1α, MIP-2, and TNFα, suggesting that cau-
tion in its use is required. We then decided to assess the effect 
of the analogue TMX-306, which is a molecular simplification 
of TMX-302 resulting from deletion of the triazol ring. It is rel-
evant to mention that the intraperitoneal injection of 200 nmoles 
TMX-306 did not cause statistically significant changes in the 
number of monocytes, macrophages, neutrophils, T cells, or B 
cells in the bone marrow, spleen, and blood circulation in mice 
(Figure S1 in Supplementary Material). TMX-306 (500 nmoles/
kg,  subcutaneous) inhibited LPS-induced AHR as well as neutro-
philic infiltration in samples of bronchoalvelar lavage (data not 
shown). Because the lungs provide a suitable route for aerosol 
delivery, we also tested the prophylactic treatment with aero-
solized TMX-306 (6 mg/mL), which turned out to be effective 
in this model, preventing both eosinophilic infiltration and AHR 
triggered by allergen challenge. However, using a long-term 
model of asthma, TMX-306 (70 nmoles/mouse, intranasal) failed 
to modify the ongoing pathological changes triggered by allergen 
provocation, whereas the glucocorticoid agent dexamethasone 
was shown to be clearly active. These findings might suggest that, 
despite inhibiting LPS- and allergen-induced lung inflammation 
and AHR as given prophylactically, TMX-306 would not be as 
effective in modifying already established asthmatic changes fol-
lowing therapeutic administration.
In this study, we also investigated whether or not the phar-
macological modulation of TLR7 with TMX-306 could be used 
to reduce silicosis. Remarkably contrasting with the lack of 
efficacy of the interventional TMX-306 treatment on experi-
mental asthma, the therapeutic intranasal administration of this 
compound clearly attenuated lung inflammation, granuloma 
formation, fibrosis, and the functional respiratory changes 
noted in response to silica particles. Current thinking is that the 
pathogenesis of silicosis is largely attributed to the direct damage 
by silica particles to alternatively activated alveolar macrophages 
and DCs, engaged in the recognition, uptake, and clearance of 
silica particles and other environmental particulate matters that 
traffic in the lung (14, 51). When this barrier is broken, free silica 
crystals accumulate in the interstitial space and are taken up by 
M1 macrophages, which play a crucial role in promoting a state 
of pulmonary inflammation that evolves to granuloma formation 
and overlaps with fibrogenic areas in humans and animal models 
(14). Indeed, stronger lung inflammatory and fibrotic responses 
were noted in mice genetically deficient in macrophage receptors 
with collagenous structure (MARCO), a scavenger receptor deeply 
involved in the sense and uptake of crystalline silica by alveolar 
macrophages (52). This result gives support to the interpretation 
that M2 alveolar macrophages account for by the clearance while 
M1 interstitial macrophages drive the silica-induced inflam-
matory response (14). Remarkably, scavenger receptor class A 
type I/II (CD204) null mice fail to develop fibrosis following silica 
inhalation, in spite of keeping inflammation, suggesting that the 
CD204 are crucial to the development of fibrosis and resolution 
of inflammation (12).
In our experimental conditions, mice exposed to a single 
intranasal instillation of 10  mg of crystalized silica particles 
reacted with a progressive lung granulomatous response, which 
reach about 40% of the lung area 30  days postchallenge, as 
evidenced by scanned histopathological images of lung sections. 
In parallel, we found a marked increase in the levels of collagen 
fiber deposition, evidenced by Picrosirius red staining, which 
appeared densely distributed throughout areas occupied by 
granuloma, as previously reported (1, 35). These changes were 
clearly reversed following intranasal instillation of TMX-306, 
given at days 15, 20, and 25 post-silica. Furthermore, the exten-
sion of lung area occupied by granuloma appeared reduced in 
about 60% whereas a reduction of 95% was noted in the amount 
of deposited collagen. TMX-306 also almost abolished the 
levels of the pro-fibrotic TGF-β generated in response to silica 
exposure. Crystalline silica particles diffract light and appear as 
bright bluish specks against the dark tissue background, and can 
be seen under light microscope equipped with polarizing filters 
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(53). Using this technique, we could detect reduction of about 
40% in the number of crystals of silica dispersed in the lung 
interstitial space, strongly suggesting that TMX-306, by reduc-
ing areas of granuloma and fibrosis, is probably favoring silica 
particle mobility and clearance from the lung through lymphatic 
draining. In fact, prior investigations have demonstrated that 
silica particles can be drained by the lymphatic system to the 
lymph nodes, particularly under conditions of effective anti-
silicosis therapy (1).
Apart from the distinct impact on the silica-induced fibrotic 
response, our findings are very much in line with those ones 
reported by Re and collaborators (54). These authors found 
a significant reduction of lung inflammation and granuloma 
formation in MyD88-KO mice after silica, giving support to the 
interpretation that MyD88-related innate immunity is crucial 
in silicosis. In addition, like ours, their results showed a robust 
reduction in the fibrotic response to silica in granuloma areas, 
with the difference that increased levels of silica-induced collagen 
deposition were detected throughout the lung parenchymal area 
(54), suggesting that inflammatory and fibrotic responses to silica 
can be uncoupled, which did not happen in our experimental 
conditions.
We cannot exclude the possibility that the PEGylated com-
pounds are simply less potent than the full agonist TMX-202, 
without any necessary impact on their efficacy on the TLR7. 
In addition, contrary to TMX-202, the intravenous administra-
tion of  PEGylated analogues such as TMX-302 and others 
(200  nmoles/kg) failed to alter the systemic baseline levels of 
pro-inflammatory cytokines such as TNF-α and IL-6 (data not 
shown). Further studies and more accurate toxicological inves-
tigations should be carried out on candidate compounds such as 
TMX-302 and TMX-306.
In conclusion, these findings provide a comprehensive com-
parison of the anti-inflammatory effectiveness of two PEGylated 
TLR7 partial agonists, concerning distinct lung pathological 
conditions and several routes of administration. The results 
suggest that the putative clinical application of TMX-302 in lung 
disorders should be examined with caution because of its direct 
pro-inflammatory effects. Moreover, in this context, TMX-306 
seems to be comparatively more effective and safer, deserving 
further investigations in drug development particularly for 
silicosis.
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